×
About 2,520 results

ALLMedicine™ Anal Cancer Center

Research & Reviews  826 results

Design of the anal cancer/HSIL outcomes research study (ANCHOR study): A randomized stu...
https://doi.org/10.1016/j.cct.2022.106679
Contemporary Clinical Trials; Lee JY, Lensing SY et. al.

Jan 13th, 2022 - It is well established that persons living with HIV (PLWH) have highly elevated rates of anal HSIL and anal cancer compared with those who are not living with HIV. The 5-year risk of anal cancer following anal HSIL has been reported to be as high ...

Perceptions of Anal Cancer Risk Among HIV-Positive and High-Risk HIV-Negative Women.
https://doi.org/10.1097/LGT.0000000000000652
Journal of Lower Genital Tract Disease; Wells J, Chandler R et. al.

Jan 13th, 2022 - Women living with HIV (WLWH) have a greater risk of anal cancer than women without HIV; however, there are limited studies that examine awareness of anal cancer risk among WLWH and "high-risk" HIV-negative women. This study examines risk factors f...

Collecting and Studying Tissue Samples From Patients With HIV-Associated Malignancies
https://clinicaltrials.gov/ct2/show/NCT01567722

Jan 11th, 2022 - OBJECTIVES: To obtain high-quality, clinically annotated tissue from patients with human immunodeficiency virus (HIV)-1 malignancy. To study clinical, genetic, and immunologic parameters that have prognostic significance and/or are involved in the...

Evaluation of prognostic factors after primary chemoradiotherapy of anal cancer: A mult...
https://doi.org/10.1016/j.radonc.2021.12.050
Radiotherapy and Oncology : Journal of the European Socie... Martin D, Schreckenbach T et. al.

Jan 10th, 2022 - Prognosis after chemoradiotherapy (CRT) for anal squamous cell carcinoma (ASCC) shows marked differences among patients according to TNM subgroups, however individualized risk assessment tools to better stratify patients for treatment (de-) escala...

see more →

Guidelines  7 results

Anal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up☆.
https://doi.org/10.1016/j.annonc.2021.06.015
Annals of Oncology : Official Journal of the European Soc... Rao S, Guren MG et. al.

Jun 28th, 2021 - Anal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up☆.|2021|Rao S,Guren MG,Khan K,Brown G,Renehan AG,|diagnosis,epidemiology,therapy,

Cancer in People Living With HIV, Version 1.2018, NCCN Clinical Practice Guidelines in ...
https://doi.org/10.6004/jnccn.2018.0066
Journal of the National Comprehensive Cancer Network : JN... Reid E, Suneja G et. al.

Aug 14th, 2018 - People living with HIV (PLWH) are diagnosed with cancer at an increased rate over the general population and generally have a higher mortality due to delayed diagnoses, advanced cancer stage, comorbidities, immunosuppression, and cancer treatment ...

Anal Carcinoma, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology.
https://doi.org/10.6004/jnccn.2018.0060
Journal of the National Comprehensive Cancer Network : JN... Benson AB, Venook AP et. al.

Jul 15th, 2018 - The NCCN Guidelines for Anal Carcinoma provide recommendations for the management of patients with squamous cell carcinoma of the anal canal or perianal region. Primary treatment of anal cancer usually includes chemoradiation, although certain les...

2016 IANS International Guidelines for Practice Standards in the Detection of Anal Canc...
https://doi.org/10.1097/LGT.0000000000000256
Journal of Lower Genital Tract Disease; Hillman RJ, Cuming T et. al.

Aug 26th, 2016 - To define minimum standards for provision of services and clinical practice in the investigation of anal cancer precursors. After initial face to face meetings of experts at the International Papillomavirus meeting in Lisbon, September 17 to 21, 2...

Anal cancer: ESMO-ESSO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and ...
https://doi.org/10.1093/annonc/mdu159
Annals of Oncology : Official Journal of the European Soc... Glynne-Jones R, Nilsson PJ et. al.

Jul 9th, 2014 - Anal cancer: ESMO-ESSO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up.|2014|Glynne-Jones R,Nilsson PJ,Aschele C,Goh V,Peiffert D,|diagnosis,therapy,standards,

see more →

Drugs  2 results see all →

Clinicaltrials.gov  42 results

Collecting and Studying Tissue Samples From Patients With HIV-Associated Malignancies
https://clinicaltrials.gov/ct2/show/NCT01567722

Jan 11th, 2022 - OBJECTIVES: To obtain high-quality, clinically annotated tissue from patients with human immunodeficiency virus (HIV)-1 malignancy. To study clinical, genetic, and immunologic parameters that have prognostic significance and/or are involved in the...

Deciphering Mechanisms Underlying Cancer Immunogenicity
https://clinicaltrials.gov/ct2/show/NCT03958240

Dec 9th, 2021 - This trial is a translational, open-label, multicentric, prospective cohort study of 900 patients aiming to describe the PD-1 (programmed death) expression in T cells (T lymphocytes) in different solid tumors. The study will be conducted on a popu...

M7824 in Subjects With HPV Associated Malignancies
https://clinicaltrials.gov/ct2/show/NCT03427411

Dec 8th, 2021 - Background: Metastatic or refractory/recurrent HPV associated malignancies (cervical, anal, oropharyngeal cancers etc.) are often incurable and poorly palliated by standard therapies. TGF R1 pathway signaling and overexpression are significantly a...

Prevention and Control of Neoplasms Associated With HPV in High-risk Groups in Mexico City: The Condesa Study
https://clinicaltrials.gov/ct2/show/NCT05149248

Dec 8th, 2021 - Men who have sex with men (MSM), people with HIV, homeless people (many of whom participate in survival sex), female sex workers, transgender women and rape victims are at high risk for human papillomavirus (HPV) infection and consequently develop...

Repeat CT Scans for Evaluation of Inter- and Intrafraction Motion and it's Effect on Radiotherapy Dose Distribution During Curative Radiotherapy for Pelvic Tumours
https://clinicaltrials.gov/ct2/show/NCT03022539

Oct 21st, 2021 - Radiotherapy (combined with chemotherapy) is commonly used in the curative treatment of pelvic tumours, such as in cervical, vulvar and anal cancer. In these patients, cure rates are high but may be associated with significant treatment-related to...

see more →

News  128 results

Dr. Eng on Emerging Agents for Treatment of Anal Cancer
https://www.onclive.com/view/dr-eng-on-emerging-agents-for-treatment-of-anal-cancer

Oct 6th, 2021 - Cathy Eng, MD, FACP, professor, director, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, Network Clinical Research, associate medical director, Colorectal Center, the University of Texas MD Anderson Cancer Center, di...

Mount Sinai Receives NCI Grant to Study Anal Cancer Screening in High-Risk Women
https://www.onclive.com/view/mount-sinai-receives-nci-grant-to-study-anal-cancer-screening-in-high-risk-women

Aug 10th, 2021 - The Icahn School of Medicine at Mount Sinai has been awarded a grant of more than $4 million by the National Cancer Institute for a large-scale study to evaluate anal cancer screening in high-risk women who have been previously diagnosed with huma...

Call to Eradicate All Types of HPV Cancers, not Just Cervical
https://www.medscape.com/viewarticle/948120

Mar 25th, 2021 - The World Health Organization's (WHO) call for the elimination of cervical cancer worldwide is a laudable goal, and one that many organizations across the globe have endorsed. Yet some would say that that goal goes only halfway, and that the real ...

The Vanguard of HIV Care: Don't Forget This Screening
https://www.medscape.com/viewarticle/946148

Feb 22nd, 2021 - HIV-positive patients who are adherent with antiretroviral medications are achieving undetectable or very low levels of HIV viremia and living longer. In response, clinical care is continually adapting to the dramatically altered natural history o...

FDA Grants Priority Review to Retifanlimab for Squamous Cell Carcinoma of the Anal Canal
https://www.onclive.com/view/fda-grants-priority-review-to-retifanlimab-for-squamous-cell-carcinoma-of-the-anal-canal

Jan 21st, 2021 - The FDA has granted priority review to a biologics license application (BLA) for retifanlimab (INCMGA 0012) for the treatment of adult patients with locally advanced or metastatic squamous cell carcinoma of the anal canal (SCAC) who were intoleran...

see more →

Patient Education  3 results see all →